Commentary on Greenberg et al., “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions” [ Alzheimer's Dement . 2023; 9(4):e12426. doi.org/10.1002/trc2.12426]

Documenti analoghi

• Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
  di: Xiaojuan Li, et al.
  Pubblicazione: (2025)
• Unforgettable: The power of community in the pursuit of health equity for Alzheimer's disease and other dementia
  di: Beverly M. Berry, et al.
  Pubblicazione: (2025)
• Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
  di: Ronald C. Petersen, et al.
  Pubblicazione: (2025)
• Infusion‐related reactions in donanemab‐treated participants with early symptomatic Alzheimer's disease
  di: Paul Ardayfio, et al.
  Pubblicazione: (2026)
• Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
  di: Linda J. Van Eldik, et al.
  Pubblicazione: (2024)